Today’s episode of The Oncology Journal Club is the third of our ESMO Special Episodes featuring Breast Cancer…
The Oncology Podcast, brought to you by Oncology News Australia, is proud to present Episode 15 in our series The Oncology Journal Club, the third of our ESMO Special Episodes.
Today’s ESMO Episode features Amelia McCartney chatting with Eva Segelov and our favourite new guest interviewer, Steve Vogl from New York. It’s an entertaining and detailed discussion so we hope you find value in this expert analysis.
“It looks like a web woven by an intoxicated spider,” Steven Vogl, New York
Next week we have a standard format episode covering a wide range of subjects and papers, and also an extended interview with Steven Vogl as part of our ‘The OJC Meets…’ sister series so if you’ve enjoyed hearing from ‘Vogl, New York’ watch out for this one.
With the usual top quality banter, papers you won’t hear of anywhere else and expert analysis from our Hosts, you are in for another great episode of The Oncology Journal Club.
About The Oncology Journal Club:
We have taken an old concept and updated it with a new format. In each episode a team of expert contributors will review topical journal papers and interview special guests who are leaders in their fields to help keep you informed of the latest developments on the go.
With The Oncology Podcast – and The Oncology Journal Club in particular – we are aiming to deliver oncology news differently,” Rachael Babin, Editor-in-Chief, Oncology News.
The Oncology Journal Club is hosted by Professor Eva Segelov, from Monash University. Eva is joined by Dr Craig Underhill from Albury-Wodonga and Professor Hans Prenen from Antwerp, Belgium. We hope you enjoy listening and find this a valuable and entertaining resource.
This Week’s Papers:
- Miles, D, et al. Primary results from IMpassion131, a double-blind placebo-controlled randomised phase III trial of first-line paclitaxel (PAC) ± atezolizumab (atezo) for unresectable locally advanced/metastatic triple-negative breast cancer (mTNBC). Annals of Oncology (2020) 31 (suppl_4): S1142-S1215. 10.1016/annonc/annonc325. Access online here.
- Emens, L, et al. IMpassion130: Final OS analysis from the pivotal phase III study of atezolizumab + nab-paclitaxel vs placebo + nab-paclitaxel in previously untreated locally advanced or metastatic triple-negative breast cancer. Annals of Oncology (2020) 31 (suppl_4): S1142-S1215. 10.1016/annonc/annonc325. Access online here.
- Harbeck N,. et al. IMpassion031: Results from a phase III study of neoadjuvant (neoadj) atezolizumab + chemotherapy in early triple-negative breast cancer (TNBC). Annals of Oncology (2020) 31 (suppl_4): S1142-S1215. 10.1016/annonc/annonc325. Access online here.
- Johnston, S, et al. Abemaciclib in high risk early breast cancer. Annals of Oncology (2020) 31 (suppl_4): S1142-S1215. 10.1016/annonc/annonc325. Access online here.
- Mayer, E, et al. PALLAS: A randomized phase III trial of adjuvant palbociclib with endocrine therapy versus endocrine therapy alone for HR+/HER2- early breast cancer. Annals of Oncology (2020) 31 (suppl_4): S1142-S1215. 10.1016/annonc/annonc325. Access online here.
This Week’s Team:
Professor Eva Segelov
Professor Eva Segelov is a Medical Oncologist and is Director of Oncology at Monash University and Monash Health, Melbourne, Victoria, previously Senior Medical Oncologist at St Vincent’s Hospital, St Vincent’s Private Hospital and St Vincent’s Clinic and Associate Professor of Medicine, University of New South Wales.
Eva has an interest in academic clinical trials in GI and breast cancer and has been a member of the AGITG since 2003. She has clinical trials expertise, links with national and international trials groups, and extensive experience with adult medical education.
Dr Amelia McCartney is a medical oncologist who obtained her medical degree from the University of Sydney in 2004. Prior to her medical studies, she graduated with a Bachelor of Science and a Bachelor of Arts from the Australian National University. She completed her specialist training in Victoria in centres including Epworth Freemasons, the Peter MacCallum
Cancer Centre, University Hospital Geelong and Royal Melbourne Hospital.
She completed a four‐year fellowship in translational and clinical breast cancer research under the supervision and mentorship of Dr Angelo Di Leo in Prato, Italy. Dr McCartney’s particular areas of research interest are the discovery and trialling of biomarkers related to prognosis and early response to treatment, mechanisms of treatment resistance, and strategies of safely de‐escalating breast cancer therapies. . She is a serving member of several international collaborative trial committees under the auspices of the International Breast Cancer Study Group (IBCSG) and the Breast International Group (BIG).
Steven Vogl is a medical oncologist in private practice in the Bronx, New York. He pays attention at meetings and occasionally asks a question.
Rachael Babin is Editor-in-Chief of The Oncology Newsletter and Publisher of www.oncologynews.com.au. For regular oncology updates for healthcare professionals, please subscribe to The Oncology Newsletter.
With thanks to Eva Segelov, Amelia McCartney, our Special Guest Interviewer Steven Vogl and Graham Knowles.